These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 28540827)

  • 1. Complete cytoreductive surgery plus HIPEC for peritoneal metastases from unusual cancer sites of origin: results from a worldwide analysis issue of the Peritoneal Surface Oncology Group International (PSOGI).
    Goéré D; Passot G; Gelli M; Levine EA; Bartlett DL; Sugarbaker PH; Glehen O
    Int J Hyperthermia; 2017 Aug; 33(5):520-527. PubMed ID: 28540827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peritoneal carcinomatosis from unusual cancer origins: Is there a role for hyperthermic intraperitoneal chemotherapy?
    Honoré C; Goéré D; Macovei R; Colace L; Benhaim L; Elias D
    J Visc Surg; 2016 Apr; 153(2):101-7. PubMed ID: 26698380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peritoneal Carcinomatosis of Rare Ovarian Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Multi-Institutional Cohort from PSOGI and BIG-RENAPE.
    Mercier F; Bakrin N; Bartlett DL; Goere D; Quenet F; Dumont F; Heyd B; Abboud K; Marolho C; Villeneuve L; Glehen O; ;
    Ann Surg Oncol; 2018 Jun; 25(6):1668-1675. PubMed ID: 29637438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for limited peritoneal metastasis. The PSOGI international collaborative registry.
    Arjona-Sanchez A; Aziz O; Passot G; Salti G; Esquivel J; Van der Speeten K; Piso P; Nedelcut DS; Sommariva A; Yonemura Y; Turaga K; Selvasekar CR; Rodriguez-Ortiz L; Sanchez-Hidalgo JM; Casado-Adam A; Rufian-Peña S; Briceño J; Glehen O
    Eur J Surg Oncol; 2021 Jun; 47(6):1420-1426. PubMed ID: 33298341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: Results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI).
    Bushati M; Rovers KP; Sommariva A; Sugarbaker PH; Morris DL; Yonemura Y; Quadros CA; Somashekhar SP; Ceelen W; Dubé P; Li Y; Verwaal VJ; Glehen O; Piso P; Spiliotis J; Teo MCC; González-Moreno S; Cashin PH; Lehmann K; Deraco M; Moran B; de Hingh IHJT
    Eur J Surg Oncol; 2018 Dec; 44(12):1942-1948. PubMed ID: 30075978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytoreduction and HIPEC in the treatment of "unconventional" secondary peritoneal carcinomatosis.
    Cardi M; Sammartino P; Mingarelli V; Sibio S; Accarpio F; Biacchi D; Musio D; Sollazzo B; Di Giorgio A
    World J Surg Oncol; 2015 Oct; 13():305. PubMed ID: 26493405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peritoneal metastases from small bowel cancer: Results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in The Netherlands.
    van Oudheusden TR; Lemmens VE; Braam HJ; van Ramshorst B; Meijerink J; te Velde EA; Mehta AM; Verwaal VJ; de Hingh IH
    Surgery; 2015 Jun; 157(6):1023-7. PubMed ID: 25818658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status and future prospects of clinical trials on CRS + HIPEC for gastric cancer peritoneal metastases.
    Ji ZH; Peng KW; Yu Y; Li XB; Yonemura Y; Liu Y; Sugarbaker PH; Li Y
    Int J Hyperthermia; 2017 Aug; 33(5):562-570. PubMed ID: 28124576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is there an oncological interest in the combination of CRS/HIPEC for peritoneal carcinomatosis of HCC? Results of a multicenter international study.
    Mehta S; Schwarz L; Spiliotis J; Hsieh MC; Akaishi EH; Goere D; Sugarbaker PH; Baratti D; Quenet F; Bartlett DL; Villeneuve L; Kepenekian V;
    Eur J Surg Oncol; 2018 Nov; 44(11):1786-1792. PubMed ID: 29885982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis.
    Wu X; Li Z; Li Z; Jia Y; Shan F; Ji X; Bu Z; Zhang L; Wu A; Ji J
    J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iterative procedures combining cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for isolated peritoneal recurrence.
    Vaira M; Robella M; Mellano A; Sottile A; De Simone M
    Int J Hyperthermia; 2014 Dec; 30(8):565-9. PubMed ID: 25430988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammatory bowel disease drastically affects the prognosis of patients treated for peritoneal metastases with combined cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A multicenter study.
    Hammoudi N; Eveno C; Lambert J; Maillet M; Glehen O; Goere D; Lourenco N; Allez M; Aparicio T; Pocard M; Gornet JM;
    Eur J Surg Oncol; 2018 Jun; 44(6):799-804. PubMed ID: 29650418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of ovarian metastases of colorectal and appendiceal carcinoma in the era of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Kuijpers AM; Mehta AM; Aalbers AG; van Driel WJ; Boot H; Verwaal VJ
    Eur J Surg Oncol; 2014 Aug; 40(8):937-42. PubMed ID: 24630923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrence and Survival Outcomes After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Small Bowel Adenocarcinoma.
    Saxena A; Valle SJ; Liauw W; Morris DL
    Anticancer Res; 2017 Oct; 37(10):5737-5742. PubMed ID: 28982894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cytoreductive surgery and HIPEC for peritoneal malignancies in children].
    Seitz G; Fuchs J; Königsrainer I; Warmann SW; Königsrainer A; Beckert S
    Zentralbl Chir; 2014 Dec; 139(6):607-12. PubMed ID: 25531634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytoreductive surgery and HIPEC improve survival compared to palliative chemotherapy for biliary carcinoma with peritoneal metastasis: A multi-institutional cohort from PSOGI and BIG RENAPE groups.
    Amblard I; Mercier F; Bartlett DL; Ahrendt SA; Lee KW; Zeh HJ; Levine EA; Baratti D; Deraco M; Piso P; Morris DL; Rau B; Tentes AAK; Tuech JJ; Quenet F; Akaishi E; Pocard M; Yonemura Y; Lorimier G; Delroeux D; Villeneuve L; Glehen O; Passot G;
    Eur J Surg Oncol; 2018 Sep; 44(9):1378-1383. PubMed ID: 30131104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.
    Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS
    World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overall survival of pseudomyxoma peritonei and peritoneal mesothelioma patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy can be predicted by computed tomography quantified sarcopenia.
    Galan A; Rousset P; Mercier F; Képénékian V; Valette PJ; Glehen O; Passot G
    Eur J Surg Oncol; 2018 Nov; 44(11):1818-1823. PubMed ID: 30143249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
    Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V
    Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel improves survival for patients with peritoneal carcinomatosis from abdominal and pelvic malignancies.
    Wu HT; Yang XJ; Huang CQ; Sun JH; Ji ZH; Peng KW; Zhang Q; Li Y
    World J Surg Oncol; 2016 Sep; 14(1):246. PubMed ID: 27633880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.